Review Shows AI Could Be Pivotal in Infectious Disease

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
256
Review Shows AI Could Be Pivotal in Infectious Disease Prevention

The worst of the coronavirus pandemic may be in the past, but it showed just how badly a fast-spreading infectious disease could affect the world. Most countries were woefully unprepared to deal with a medical event of that magnitude, and for the most part, the world still isn’t equipped to deal with such a pandemic.

Millions of lives were lost worldwide during the pandemic, and to this day thousands of people across the world are still dealing with long Covid symptoms. Researchers recently discussed the possibility of using machine learning and artificial intelligence to prevent future disease outbreaks and pandemics.

Published in the “Science” journal, the review covered the challenges involved in predicting and preventing infectious disease outbreaks and the future role that artificial intelligence could play. The study noted that infectious diseases still present a global challenge that our advancements in pharmaceuticals, molecular genetics and computing power haven’t been able to address.

Infectious diseases such as ebola, Zika, Marburg virus and H5N1 influenza have the potential to cripple the global economy and, even more significantly, take countless lives if they get out of hand. Furthermore, dangerous pathogens such as multidrug-resistant tuberculosis and carbapenem-resistant Enterobacteriaceae (CRE) present a constant risk of widespread disease outbreaks.

As the world becomes even more interconnected, it is crucial that we develop ways of preventing infectious disease outbreaks before they spread across borders and cause immense stress on already-stretched healthcare systems. Leveraging increasingly advancing software could give us the tools we need to detect infectious diseases as early as possible and deploy preventative and treatment options before they proliferate.

Machine learning (ML) and artificial intelligence (AI) present the most attractive options as they allow for the study and analysis of gargantuan data sets. ML is already being used to train computers to make more accurate predictions and has aided in searches of small-molecule databases.

Using tools such as machine learning makes it possible for scientists and physicians to examine genetic information in the greatest detail to predict antigens and discover crucial molecular structures that control immune responses and interactions between pathogens and hosts.

Aside from their predictive features, AI and ML can also help in the development of infectious disease treatments. For instance, systems such as NVIDIA’s BioNeMo and GPT-4 can aid in our understanding of fundamental chemical and biological dynamics by combining various scientific data streams.

Although AI and ML are still relatively new fields, they have already played a major role in modernizing medicine and improving treatment outcomes. The technology will most likely be as useful in developing preventative and treatment strategies for infectious diseases.

In the meantime, companies such as BiondVax Therapeutics Ltd. (NASDAQ: BVXV) are working to bring to market immunotherapies targeting infectious diseases so that their outbreaks affect as few people as possible.

NOTE TO INVESTORS: The latest news and updates relating to BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are available in the company’s newsroom at https://ibn.fm/BVXV

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer


BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links

BVXV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 37

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 28

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 32

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 36

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 30

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading
Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 23

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 36

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Technologies Unveiled by LG Innotek at CES 2025

Updated Category News Views 383

Innovative Showcase by LG Innotek at CES 2025 LG Innotek has exciting plans for CES 2025, showcasing its commitment to revolutionizing future mobility. This year, the company aims to highlight its advanced technologies at a well-organized exhibition booth set within the bustling West Hall. A Focus on Future Mobility Technologies At CES 2025, LG Innotek will present a...

Continue Reading
Alumis and ACELYRIN Merger: A New Era for Biopharma Innovation

Updated Category News Views 277

Alumis and ACELYRIN Merge to Forge a New Path in Biopharma The biopharmaceutical landscape is about to witness a significant transformation as Alumis Inc. (NASDAQ: ALMS) and ACELYRIN, INC. (NASDAQ: SLRN) announce their merger. This strategic alliance aims to innovate, develop, and commercialize new therapies for immune-mediated diseases. With top-tier clinical programs...

Continue Reading
Legal Reminder for ICON Shareholders: Act Before Deadline

Updated Category News Views 147

Important Update for ICON plc Shareholders In a significant legal development, shareholders of ICON plc need to be aware of a class action lawsuit that has implications for their investments. If you have incurred losses exceeding $100,000, it is essential to act swiftly, as the deadline for filing lead plaintiff applications is approaching. This lawsuit originates from...

Continue Reading
Corvus Pharmaceuticals to Showcase Innovations at Investment Event

Updated Category News Views 50

Corvus Pharmaceuticals to Present at Major Investment Conference BURLINGAME, Calif. — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a prominent name in the clinical-stage biopharmaceutical sector, is thrilled to announce that its president and CEO, Richard A. Miller, M.D., along with Jeffrey Arcara, the chief business officer, will be participating in one-on-one meetings...

Continue Reading
Discover Promising Dividend Stocks with Robust Growth Potential

Updated Category News Views 122

Exploring Reliable Dividend Stocks with Growth Potential Investors have found that dividend stocks generally offer a compelling annual return averaging 9.2% since 1973, showing less volatility than the broader market index. These investments can provide a steady income stream while also having a significant upside potential. In this article, we delve into three stocks...

Continue Reading